Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 6Liver Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Turcot syndrome 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Meningioma 1Lung Neoplasms 1Liver Diseases 1Hepatocellular Carcinoma Non-resectable 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Endometrioid 1

Interventions

Early Intervention, Educational 13Oxaliplatin 12Radiotherapy 11Fluorouracil 10Exercise 10Counseling 10Methods 8Surgical Procedures, Operative 7Neoadjuvant Therapy 7Drug Therapy 7Magnetic Resonance Spectroscopy 6Laparoscopy 6Capecitabine 6Surveys and Questionnaires 5Standard of Care 5Proctectomy 5Preoperative Exercise 5Leucovorin 5Psychiatric Rehabilitation 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Blood Specimen Collection 4Biopsy 4Bevacizumab 4X-Rays 3Transanal Endoscopic Surgery 3Robotic Surgical Procedures 3Mastectomy, Segmental 3Irinotecan 3Ileostomy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Rectal Neoplasms × sintilimab × Clear all
NCT07474103 2026-03-16

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase NA Recruiting
49 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡